OncoMatch/Clinical Trials/NCT04329728
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Is NCT04329728 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AVM0703 for lymphoid malignancies.
Treatment: AVM0703 — This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: autologous hematopoietic cell transplant — relapsed/refractory
R/R after autologous hematopoietic cell transplant (HCT)
Must have received: CAR-T cell therapy — relapsed/refractory
R/R after chimeric antigen receptor T-cell (CAR T) therapy
Must have received: anti-CD20 antibody — relapsed/refractory
R/R after ≥2 lines of therapy including anti-CD20 antibody and failed, intolerant or ineligible for polatuzamab vedotin
Must have received: Bruton's tyrosine kinase (BTK) inhibitor (acalabrutinib) — relapsed/refractory
failed acalabrutinib or be R/R after ≥2 lines of therapy including at least 1 of the following: a Bruton's tyrosine kinase (BTK) inhibitor, bortezomib, or lenalidomide
Must have received: bortezomib (bortezomib) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a Bruton's tyrosine kinase (BTK) inhibitor, bortezomib, or lenalidomide
Must have received: lenalidomide (lenalidomide) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a Bruton's tyrosine kinase (BTK) inhibitor, bortezomib, or lenalidomide
Must have received: methotrexate (methotrexate) — relapsed/refractory
R/R after ≥1 line of therapy including methotrexate (unless intolerant to methotrexate)
Must have received: venetoclax (venetoclax) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a BTK inhibitor, venetoclax, idelalisib, or duvelisib
Must have received: idelalisib (idelalisib) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a BTK inhibitor, venetoclax, idelalisib, or duvelisib
Must have received: duvelisib (duvelisib) — relapsed/refractory
R/R after ≥2 lines of therapy including at least 1 of the following: a BTK inhibitor, venetoclax, idelalisib, or duvelisib
Must have received: allogeneic hematopoietic cell transplant — relapsed/refractory
R/R after allogeneic HCT
Must have received: inotuzumab ozogamicin (inotuzumab ozogamicin) — relapsed/refractory
≥2 lines of therapy including approved CAR T cell therapies, inotuzumab ozogamicin, or blinatumomab
Must have received: blinatumomab (blinatumomab) — relapsed/refractory
≥2 lines of therapy including approved CAR T cell therapies, inotuzumab ozogamicin, or blinatumomab
Must have received: nelarabine (nelarabine) — relapsed/refractory
≥2 lines of therapy including nelarabine
Lab requirements
Blood counts
Absolute neutrophil count ≥0.05 × 10^9/L; Platelet count ≥25 × 10^9/L; Hemoglobin ≥6.5 g/dL
Kidney function
Glomerular filtration rate ≥30 mL/min; except for patients on metformin at baseline GFR must be ≥45 mL/min
Liver function
Aspartate aminotransferase or alanine aminotransferase ≥2.5 × ULN, unless due to the disease; Total bilirubin <1.5 × ULN (if secondary to Gilbert's syndrome, <3 × ULN is permitted), unless due to the disease
Cardiac function
Minimum level of pulmonary reserve defined as <Grade 2 dyspnea and pulse oximetry ≥92% on room air
Screening laboratory values that meet all of the following criteria: ... Minimum level of pulmonary reserve defined as <Grade 2 dyspnea and pulse oximetry ≥92% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Los Angeles Cancer Network · Los Angeles, California
- UCLA Medical Center of Hematology/Oncology · Los Angeles, California
- Innovative Clinical Research Institute · Whittier, California
- ASCLEPES Research Centers · Weeki Wachee, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04329728 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received autologous hematopoietic cell transplant and CAR-T cell therapy.
Is there an age limit?
Yes. Patients must be 95 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify